MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Johnson & Johnson’s Cordis bails on stents

Johnson & Johnson’s Cordis bails on stents

By

Cordis

One of the biggest players in the coronary stent market is getting out of the business.

Cordis Corp., one of the medical device arms at Johnson & Johnson (NYSE:JNJ), announced the decision this morning, saying it will shut down development of its next-generation Nevo drug-eluting stent and stop making the Cypher DES line altogether by the end of 2011.

“Due to evolving market dynamics in the drug-eluting stent business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market,” Cordis group chair and worldwide chairman Seth Fischer said in prepared remarks.

Those dynamics include lower demand, pricing and reimbursement pressure and a more stringent regulatory environment, Cordis said, noting that "unlicensed competition from products that infringe Cordis patents, both owned and licensed" has cut into Cypher’s market share and "dampened the prospects" for commercializing the Nevo stent.

"At the same time, long-term data show some competitive DES offerings will adequately meet patients’ medical needs once Cordis exits the market," the company said in a press release.

In a separate release, J&J said it expects to log $500 million to $600 million in after-tax charges as a result of the plan, which will also mean layoffs for up to 1,000 workers. The move also means Cordis will shutter plants in Ireland and Puerto Rico and consolidate its research & development efforts in Fremont, Calif.

Cordis will focus its efforts on its BioSense Webster division, which makes electro-physiology products for cardiac applications and on its own, non-DES offerings in the cardiology and endovascular spaces. Those businesses threw off $1.9 billion in sales last year, excluding the drug-eluting stents operation, the company said.

In case you missed it

RSS From Medical Design & Outsourcing

  • Edwards Lifesciences stock slides on Q3 financial results
    Edwards Lifesciences (NYSE: EW) reported third-quarter financial results today that exceeded Wall Street’s expectations on profits but narrowly missed on sales. The Irvine, California–based cardio device company reported earnings of $340.1 million (or 54¢ per share) off sales of $1.31 billion. That’s a 4.6% increase from Q3 2020’s earnings of $325.2 million (52¢ per share) off sales… […]
  • BICO’s Scienion and Cellenion launch SpheroOne large-particle sorter and dispenser
    BICO Group subsidiaries Scienion and Cellenion today announced the launch of their SpheroOne single large-particle sorter and dispenser for drug testing using complex in-vitro 3D models. The SpheroOne platform can dispense individual spheroids, organoids and tumoroids, handling cellular aggregates ranging from 80 µm to 600 µm and complementing Cellenion’s CellenOne platform for sorting and dispensing… […]
  • Thermo Fisher Scientific ticks up on Street-beating Q3 results
    Thermo Fisher Scientific (NYSE:TMO) today posted third-quarter results that beat the overall consensus on Wall Street. The Waltham, Massachusetts–based laboratory supply company reported profits of $1.9 billion, or $4.79 per share, on sales of $9.3 billion for the three months ended Oct. 2, for a bottom-line loss of 1.6% on sales growth of 9.49% compared with… […]
  • Emerson introduces new miniature rocker isolation valve for clinical lab instruments
    Emerson (NYSE:EMR) has launched the ASCO Series 062 rocker isolation valve, designed for hematology and immunoassay analyzers, sample preparation and pre-analytical, as well as DNA sequencing instruments. The St. Louis, Missouri-based company said the two-way and three-way valves are compact at 16mm, allowing for easy integration into complex fluid-handling manifolds while reducing their footprint, weight… […]
  • Medtronic faces longer road to renal denervation
    Medtronic (NYSE:MDT) will continue the clinical study of its Symplicity Spyral renal denervation (RDN) system for hypertension into next year after lacking the positive results needed to end enrollment early. Fridley, Minnesota-based Medtronic said last month that it hoped to present results of the Spyral HTN-ON MED trial at the Cardiovascular Research Foundation’s TCT Conference… […]
  • Cadence is expanding in Pennsylvania
    Cadence (Staunton, Virginia) announced today that it is expanding its Product Realization Center in Cranberry Township, Pennsylvania. The company expects to finish the 21,000-square-foot expansion by March 2022. The expanded manufacturing footprint will include an additional Class 7 (10,000) cleanroom by the end of 2022. “Everything lined up so well for this expansion to take… […]
  • 3M beats The Street in Q3 as healthcare sales increase year-over-year
    3M (NYSE:MMM) shares rose slightly today on third-quarter results that topped the consensus forecast. The Maplewood, Minnesota-based company posted profits of $1.4 billion, or $2.45 per share, on sales of $8.9 billion for the three months ended Sept. 30, 2021, for a 0.3% bottom-line gain on sales growth of 7.1%. Earnings per share registering at… […]
  • Powering MRIs: 3 RF interconnect considerations to save time and money
    RF interconnects, including coaxial cables and connectors, are an integral part of MRI systems. Early awareness of challenges such as transmission loss, ease of installation and infrastructure requirements can help with performance and cost optimization in the design of new MRI systems. Kai Loh, Times Microwave Systems Magnetic resonance imaging (MRI) technology has advanced rapidly… […]
  • European approval ‘a big deal’ as Medtronic moves forward with Hugo surgical robot
    There’s excitement at Medtronic after the Hugo robotic surgery platform hit a major regulatory milestone. In 2012, Covidien formed an incubator called “Project Einstein,” focusing on combining robotic technology, data and analytics. What could they create? About nine years later, the product that emerged from Project Einstein made a significant step forward when the Hugo robotic-assisted… […]
  • Orchid announces hiring of chief quality, regulatory and EH&S officer
    Orchid (Holt, Michigan) announced that Lourdes De Cardenas Alfonso has joined the company as chief quality, regulatory and EH&S officer — effective today. Lourdes joins the orthopedic implants outsourcer from Medical Card System (MCS), where she was EVP of innovation. She has over 30 years of experience in quality control, regulatory affairs, technical services, business… […]
  • Nitto Kohki introduces vacuum pump for pick-and-place applications
    Nitto Kohki USA today announced the introduction of a standalone vacuum pump device that it says is ideal for pick-and-place applications, The LV-125A (Linicon) vacuum pump is particularly useful when house air is not available, according to the company. The pump is compact, lightweight, and features an oil-less design so that it can easily fit… […]

Leave a Reply